Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Elucidating the mechanisms of action of sodium-glucose cotransporter-2 inhibitors on the different stages of human metabolic dysfunction-associated steatotic liver disease
EF 2025-26
Résumé
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30% of Canadians, progressing from reversible disease processes of toxic fat accumulation, mitochondrial damage, inflammation and fibrosis, to irreversible stages of cirrhosis and cancer. Limitations hindering development of effective therapies include inability to assess each disease process to determine drug efficacy on each process, and the lack of direct testing on human MASLD livers at different disease stages to predict clinical response and to understand the reason for a lack of response. We have surmounted both limitations by developing a unique platform for culturing very thin slices of human liver samples obtained from obese patients undergoing bariatric surgery; 80% are at different stages of MASLD. We will how drugs affect the reversible stages of MASLD with independent assays of each disease process. We will employ these strategies to elucidate the specific mechanisms of action of a class of drugs called sodium-glucose cotransporters-2 (SGLT2) inhibitors, which are commonly used to treat type-2 diabetes, and are undergoing clinical trials to treat MASLD. However, the basis of SGLT2 inhibitors’ therapeutic actions on human MASLD livers per se and at what stage of disease these drugs are effective are remarkably unknown. We have completed some preliminary work to show one SGLT2 inhibitor to reduce fat accumulation and fibrosis. We are therefore very excited to assess the most commonly-used SGLT2 inhibitors – canagloflozin and empagliflozin. Particularly interesting is the possibility that some SGLT2 inhibitors might not act on the SGLT2 protein per se but via an undefined SGLT2-independent pathway, which I will also explore. All these I will accomplish during my M.Sci. program.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573237
Name
Bharatselvam Sharvika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the mechanisms of action of sodium-glucose cotransporter-2 inhibitors on the different stages of human metabolic dysfunction-associated steatotic liver disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Bariatric Surgery; Fibrogenesis; Hepatic Steatosis; Human Liver; In Vivo Mouse Model; Ipraglifozin; Masld; Obesity; Sodium-Glucose Cotransporters-2 Inhibitors; Type 2 Diabetes
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30% of Canadians, progressing from reversible disease processes of toxic fat accumulation, mitochondrial damage, inflammation and fibrosis, to irreversible stages of cirrhosis and cancer. Limitations hindering development of effective therapies include inability to assess each disease process to determine drug efficacy on each process, and the lack of direct testing on human MASLD livers at different disease stages to predict clinical response and to understand the reason for a lack of response. We have surmounted both limitations by developing a unique platform for culturing very thin slices of human liver samples obtained from obese patients undergoing bariatric surgery; 80% are at different stages of MASLD. We will how drugs affect the reversible stages of MASLD with independent assays of each disease process. We will employ these strategies to elucidate the specific mechanisms of action of a class of drugs called sodium-glucose cotransporters-2 (SGLT2) inhibitors, which are commonly used to treat type-2 diabetes, and are undergoing clinical trials to treat MASLD. However, the basis of SGLT2 inhibitors’ therapeutic actions on human MASLD livers per se and at what stage of disease these drugs are effective are remarkably unknown. We have completed some preliminary work to show one SGLT2 inhibitor to reduce fat accumulation and fibrosis. We are therefore very excited to assess the most commonly-used SGLT2 inhibitors – canagloflozin and empagliflozin. Particularly interesting is the possibility that some SGLT2 inhibitors might not act on the SGLT2 protein per se but via an undefined SGLT2-independent pathway, which I will also explore. All these I will accomplish during my M.Sci. program.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bharatselvam, Sharvika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~